Renaissance Capital logo

Carmell Therapeutics (Alpha Healthcare Acquisition III) Priced, Nasdaq: CTCX

Blank check company targeting a healthcare business in the US (completed 7/12/2023).

Industry: SPAC

Latest Trade: $2.20 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: -78.0%

Industry: SPAC

We are a newly organized blank check company. While we may pursue an acquisition opportunity in any business industry or sector, we intend to capitalize on our management team’s differentiated ability to source, acquire and manage a business in the healthcare industry in the United States. Our management team has an extensive track record of creating value for stockholders by acquiring attractive businesses at disciplined valuations, investing in growth while fostering financial discipline and ultimately improving financial results. Our management team is led by Rajiv Shukla, our Chairman and Chief Executive Officer, and Patrick A. Sturgeon, our Chief Financial Officer. We believe our management team’s operating and transaction experience and relationships with companies will provide us with a substantial number of potential business combination targets. Over the course of their careers, the members of our management team have developed a broad network of contacts and corporate relationships in the healthcare industry. We intend to capitalize on the ability of our management team to identify, acquire and operate a business that will benefit from their involvement by utilizing differentiating factors to our advantage.
more less
IPO Data
IPO File Date 03/04/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 15.0
Deal Size ($mm) $150
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/26/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 15.0
Deal Size ($mm) $150
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
PJT Partners
Company Data
Headquarters New York, NY, United States
Founded 2021
Employees 2

Carmell Therapeutics (Alpha Healthcare Acquisition III) (CTCX) Performance